


[Fig. 1A]


Formulation 1
Latano UD
Xalatan
ng/ml mean+/-sem
0
20
40
60
80
100
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
time (h)


[Fig. 1B]


Latano UD
Xalatan
ng/ml mean +/-sem
0
20
40
60
80
100
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
time (h)


[Fig. 1C]


Formulation 3
Latano UD
Xalatan
ng/ml mean+/-sem
0
20
40
60
80
100
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
time (h)


[Fig. 1D]


Formulation 4b
Latano UD
Xalatan
ng/ml mean+/-sem
0
20
40
60
80
100
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
time (h)


[Fig. 2A]


Intraocular pressure after topical administration in rats
n=6
Latanoprost 0,005%
Trometamol 0,25%
Xalatan 0,005%
IOP mmHg mean±sem
Time h
30
25
20
15
10
-1
0
1
2
3
4
5
6
7
8
9
10
11


[Fig. 2B]


Intraocular pressure after topical administration in rats
n=12 (10h n=6)
Latanoprost 0,0035%
Trometamol 0,1225%
Xalatan 0,005%
IOP mmHg mean±sem
Time h
30
25
20
15
10
-1
0
1
2
3
4
5
6
7
8
9
10
11


[Fig. 2C]


Intraocular pressure after topical administration of 8 days in rats
n=6
Latanoprost 0,0035%
Trometamol 0,1225%
Xalatan 0,005%
IOP mmHg meanhsem
Time h
30
25
20
15
10
-1
0
1
2
3
4
5
6
7
8
9

[Fig. 3A]


Latanoprost SDU Stability at 5° C
Latanoprost assay (%)
110,0
105,0
100,0
95,0
90,0
0 1 2 3 4 5 6 7 8 9 10
time (months)

[Fig. 3B]


Latanoprost SDU Stability at 25° C
Latanoprost assay (%)
110,0
105,0
100,0
95,0
90,0
0 1 2 3 4 5 6 7 8 9 10
Time (months)